• Fierce Pharma Geoffrey von Maltzahn at Tessera named to the 2022 most influential entrepreneurs in biopharma
• Compass Pathways Press Release COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
• Finch Therapeutics Press Release Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND
• Business Wire Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform
• PR Newswire Matterworks Anounces Updates to its Board of Directors
• PR Newswire Valo Health Acquires TARA Biosystems Creating First of its Kind Vertically Integrated Cardiovascular Platform
• Fierce Biotech Tasso, Vault Health team up to provide at-home blood testing for siteless clinical trials
• Business Wire Fierce Medtech Names Tasso as One of Its “Fierce 15” Med Tech Companies of 2021
• Business Wire 1859 Inc. Launches with $40 Million Series A to Industrialize New Medicine Discovery by Combining Artificial Intelligence and Empirical Screening Data at Scale
• Fierce Biotech Mystery no more: Mythic Therapeutics emerges with $103M to test antibody-drug conjugates in lung cancer
• Fierce Biotech Inscripta closes $150M VC round, scores first commercial buyer of CRISPR gene editing platform
• Genome Web With $6M in Seed Funding, MIT Spinout Glyphic Biotechnologies Building Proteomic Platform
• PR Newswire Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank
• OMX Press Release OMX Announces Financings of Microbiome Companies Finch Therapeutics and Freya Biosciences
• OMX Press Release OMX Ventures Completes First Closing of OMX Ventures Fund I
• OMX Press Release OMX Ventures Adds New Team Members to Expand Investment and Company Creation Activities in $150M Oversubscribed Fund I